- First-line bevacizumab plus epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) offered better OS, PFS, and objective response rates (ORRs) than EGFR-TKIs alone in patients with EGFR-mutant advanced nonsquamous NSCLC and multiple brain metastases.
Why this matters
- Brain metastasis is one of the most common distant metastases in patients with advanced NSCLC.
- 208 patients with EGFR-mutant advanced nonsquamous NSCLC and multiple brain metastases received EGFR-TKIs either alone (n=149) or with bevacizumab (n=59).
- Funding: National Natural Science Foundation of China.
- Combination therapy offered significantly better OS (29.6 vs 21.7 months; HR, 0.51; P<.001 intracranial orr vs p=".001)," systemic pfs months hr and>
- Outcomes were similar regardless of patients’ specific EGFR mutations.
- After multivariable analysis, combination therapy was associated with better intracranial PFS (HR, 0.546; P<.001 systemic pfs p and os>
- The combination group had more grade ≥3 adverse events (84.7% vs 57.0%), with the most common including hypertension, proteinuria, rash, and liver function disorder or abnormal hepatic function.
- Retrospective study.